Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry1

[1]  T. Kohno,et al.  The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer. , 2018, Lung cancer.

[2]  E. Richardsen,et al.  Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer. , 2018, Human pathology.

[3]  N. Bercovici,et al.  Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment , 2018, Proceedings of the National Academy of Sciences.

[4]  E. Richardsen,et al.  LAG‐3 in Non–Small‐cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival , 2017, Clinical lung cancer.

[5]  F. Hirsch,et al.  MHC class II expression in lung cancer. , 2017, Lung cancer.

[6]  Dave Singh,et al.  Characterisation of lung macrophage subpopulations in COPD patients and controls , 2017, Scientific Reports.

[7]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[8]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[9]  W. Cooper,et al.  The Role of Tumor‐Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Lunxu Liu,et al.  Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: A systemic review and meta-analysis , 2016, Oncotarget.

[11]  F. Pezzella,et al.  Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  G. Kang,et al.  Prognostic Implication of M2 Macrophages Are Determined by the Proportional Balance of Tumor Associated Macrophages and Tumor Infiltrating Lymphocytes in Microsatellite-Unstable Gastric Carcinoma , 2015, PloS one.

[14]  J. Austin,et al.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Brian Ruffell,et al.  Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.

[16]  M. Merad,et al.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. , 2015, American journal of respiratory and critical care medicine.

[17]  P. Ren,et al.  Interstitial tumor-associated macrophages combined with tumor-derived colony-stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non-small cell lung cancer. , 2014, The Journal of thoracic and cardiovascular surgery.

[18]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[19]  Will Liao,et al.  The cellular and molecular origin of tumor-associated macrophages , 2014, Science.

[20]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[21]  F. Donskov,et al.  Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome. , 2013, Lung cancer.

[22]  Thomas A. Wynn,et al.  Macrophage biology in development, homeostasis and disease , 2013, Nature.

[23]  Y. Kanai,et al.  Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer , 2013, British Journal of Cancer.

[24]  R. Palmqvist,et al.  Macrophages: Good guys in colorectal cancer. , 2013, Oncoimmunology.

[25]  Yuquan Wei,et al.  Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature , 2012, PloS one.

[26]  Kenji Suzuki,et al.  Prognostic Impact of CD204-Positive Macrophages in Lung Squamous Cell Carcinoma: Possible Contribution of Cd204-Positive Macrophages to the Tumor-Promoting Microenvironment , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  A. Ochiai,et al.  Prognostic impact of cancer-associated stromal cells in patients with stage I lung adenocarcinoma. , 2012, Chest.

[28]  S. H. van der Burg,et al.  Identification and manipulation of tumor associated macrophages in human cancers , 2011, Journal of Translational Medicine.

[29]  Jinyan Wang,et al.  Transition of tumor-associated macrophages from MHC class IIhi to MHC class IIlow mediates tumor progression in mice , 2011, BMC Immunology.

[30]  K. O'Byrne,et al.  The role of inflammation in the pathogenesis of non-small cell lung cancer. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[32]  A. Ochiai,et al.  Stromal Macrophage Expressing CD204 is Associated with Tumor Aggressiveness in Lung Adenocarcinoma , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  S. H. van der Burg,et al.  Anti‐inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor‐treated gastrointestinal stromal tumors , 2010, International journal of cancer.

[34]  Lunxu Liu,et al.  The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer , 2010, BMC Cancer.

[35]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[36]  Lunxu Liu,et al.  The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time , 2010, BMC Cancer.

[37]  C. Loos.  Chromogens in Multiple Immunohistochemical Staining Used for Visual Assessment and Spectral Imaging: The Colorful Future , 2010 .

[38]  T. Dønnem,et al.  The prognostic value of intraepithelial and stromal innate immune system cells in non‐small cell lung carcinoma , 2009, Histopathology.

[39]  C. Klein,et al.  Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.

[40]  P. Bradding,et al.  Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival , 2009, European Respiratory Journal.

[41]  J. Edwards,et al.  Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.

[42]  P. Allavena,et al.  Macrophage polarization in tumour progression. , 2008, Seminars in cancer biology.

[43]  A. Gemma,et al.  Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer , 2008, Cancer.

[44]  Jae Hyun Kim,et al.  High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer , 2008, British Journal of Cancer.

[45]  A. Sica,et al.  Plasticity of Macrophage Function during Tumor Progression: Regulation by Distinct Molecular Mechanisms1 , 2008, The Journal of Immunology.

[46]  W. Sauerbrei,et al.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2006, Breast Cancer Research and Treatment.

[47]  K. O'Byrne,et al.  Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S. Abe,et al.  Clinical significance of vascular endothelial growth factor‐C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma , 2005, Cancer.

[49]  Jeremy J. W. Chen,et al.  Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[51]  E. Gabrielson,et al.  High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[53]  Y. Soini,et al.  Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma. , 1999, Lung cancer.

[54]  I. Takanami,et al.  Tumor-Associated Macrophage Infiltration in Pulmonary Adenocarcinoma: Association with Angiogenesis and Poor Prognosis , 1999, Oncology.

[55]  R. Klausner,et al.  Class II MHC molecules can use the endogenous pathway of antigen presentation , 1990, Nature.

[56]  大瀧 容一.  Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma , 2012 .

[57]  S. Gordon.  Alternative activation of macrophages , 2003, Nature Reviews Immunology.